887338-40-1

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 933-67-5 7-methyl-1H-indole 
• 123892-57-9 N-tosyl-7-methylindole 

Downstream Products

• 1396259-60-1 C₃₅H₃₅NO₄ 
• 1396259-49-6 C₄₂H₄₁NO₆S 
• 1396260-29-9 1-(4-cyclopropylbenzyl)-7-methyl-3-(β-D-xylopyranosyl)-1H-indole 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors

Sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors are the current focus on the indication for the management of hyperglycemia in diabetes. Here, a novel series of C-linked indolylxyloside-based inhibitors of SGLT2 has been discovered. Structure-activity relationship studies revealed that substituents at the 7-position of the indole moiety and a p-cyclopropylphenyl group in the distal position were necessary for optimum inhibitory activity. The pharmacokinetic study demonstrates that the most potent compound 1i is metabolically stable with a low clearance in rats. In further efficacy study, 1i is found to significantly lower blood glucose levels of streptozotocin (STZ)-induced diabetic rats.

1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D